Shire, Acceleron to Collaborate on Treatments for Rare Muscle Diseases
Shire Pharmaceuticals has signed a $498 million collaboration agreement with Acceleron Pharma to develop and commercialize treatments for muscular and neuromuscular disorders.
430
Protalix Granted Fast-Track Review for Gaucher Drug
The U.S. Food and Drug Administration has granted a fast-track review to Protalix BioTherapeutics’ experimental treatment for Gaucher disease.